Skip to main content
. 2020 Sep 12;37(6):637–648. doi: 10.1007/s10585-020-10055-x

Fig. 1.

Fig. 1

Nintedanib and VEGF/Ang2 nanobody prolong animal survival. Kaplan–Meier survival curves of the four treatment groups receiving control gavage, Nintedanib, control IgG, or VEGF/Ang2 nanobody. Median survival: 32 days; n = 12 mice per group, except of control IgG group n = 14. *p < 0.05 and ***p < 0.001 Gehan–Breslow–Wilcoxon test